Medigene to Present at Upcoming Scientific Conferences

On October 16, 2024 Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, reported that it will present at the 16th Annual Protein & Antibody Engineering Summit (PEGS) to be held from November 5-7, 2024 in Barcelona as well as at the Cell 2024 conference by Oxford Global from November 6-8, 2024 in London (Press release, MediGene, OCT 16, 2024, View Source [SID1234647234]). In addition, two posters will be presented at the 39th Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) from November 6-10, 2024, in Houston, TX, USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral presentation

PEGS 2024
View Source
Location: Montjuic Palau de Congressos- Fira Barcelona, Spain
Date and time: Thursday, November 7, 2024, 8:25 am local time
Presenter: Kanuj Mishra, PhD, Team Lead & Lab Head, Innovation
Session: Next-Generation Immunotherapies
Title: Seamless Integration of a Universal Epitope into Recombinant TCRs for Tagging and Tracking of TCR-T Cells Expressing 3S TCRs

The presentation will highlight the Company’s latest technology, UniTope & TraCR, an innovative combination of universal TCR tagging and tracking. This advanced system is engineered to greatly improve the precision and efficiency of T cell receptor identification and monitoring, providing benefits for immunotherapy research and clinical applications.

Cell 2024 by Oxford Global
View Source

Panel Discussion
Location: Novotel London West, London, UK
Date/time: Wednesday, November 6, 2024, 3 p.m. local time
Presenter: Kirsty Crame, MD, Vice President, Clinical Strategy and Development
Session: Exploring Autologous Vs. Allogenic Therapies

Keynote Address
Location: Novotel London West, London, UK
Date/time: Thursday, November 7, 2024, 9.30 a.m. local time
Presenter: Kirsty Crame, MD, Vice President, Clinical Strategy and Development
Session: CGT Development
Title: Making The Ordinary Extraordinary: MDG1015 A Clinic Ready 3rd Generation TCR-T Therapy

Oral presentation
Location: Novotel London West, London, UK
Date/time: Friday, November 8, 2024, 2.20 p.m. local time
Presenter: Prof. Dolores Schendel, CSO
Session: iPSCs and stem cell therapy development
Title: TCR-T Platform for Solid Tumors

SITC 2024
View Source
Location: George R. Brown Convention Center in Houston, TX
Date and time: November 6-10, 2024 in Houston, TX

Details on the poster presentation are as follows:
Abstract and Title: " UniTope & TraCR – A universal tagging and tracking system for TCR-T cells directly integrated in recombinant TCR."
Authors: Kanuj Mishra, Justyna Ogonek, Dolores Schendel, Barbara Loesch
Abstract number: 20
Date/time: Saturday, November 9, 2024, George R. Brown Convention Center – Level 1 -Exhibit Halls AB, poster reception from 7:10-8.30 p.m.
Presenter: Barbara Loesch, PhD, Head of Technology and Innovation Department
Session: Biomarkers, Immune Monitoring and Novel Technologies

Abstract and Title: "The IFN-γ Biosensor – A universal tool for IFN-γ detection in cellular co-culture assays."
Authors: Barbara Loesch, Kanuj Mishra, Justyna Ogonek, Dolores Schendel
Abstract number: 21
Date/time: Friday, November 8, 2024, George R. Brown Convention Center – Level 1 -Exhibit Halls AB, poster reception from 5:30-7 p.m.
Presenter: Barbara Loesch, PhD, Head of Technology and Innovation Department
Session: Biomarkers, Immune Monitoring and Novel Technologies

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

On October 15, 2024 Genmab A/S (Nasdaq: GMAB) reported that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S.), as reported by Johnson & Johnson were USD 3,016 million in the third quarter of 2024 (Press release, Genmab, OCT 15, 2024, View Source [SID1234647200]). Net trade sales were USD 1,684 million in the U.S. and USD 1,332 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

On October 15, 2024 Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, reported that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Glioblastoma (Press release, Lantern Pharma, OCT 15, 2024, View Source [SID1234647216]). LP-184 is currently in a Phase 1A clinical trial designed to evaluate the safety and tolerability of the synthetically lethal investigational drug candidate in a broad range of solid tumors, including Glioblastoma (GBM). LP-184 was optimized and advanced in part with Lantern’s AI platform, RADR, to aid in the validation of mechanisms that could be exploited in the clinical setting to eradicate challenging cancers, and uncover insights in targeted patient populations. RADR is Lantern’s AI platform for cancer therapy discovery, development and rescue with over 100 billion data points and aiding in the development of both Lantern’s portfolio and development initiatives with Lantern’s collaborators.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About GBM and the need for improved and novel therapies.

Glioblastoma (GBM) affects nearly 13,000 patients annually in the US and approximately 300,000 globally, with a mortality rate of 94%. Current standard of care therapies result in a life expectancy in GBM patients of less than 15 months. A major limitation to development of new drugs in the treatment of GBM is the need for potential drugs to have the ability to cross the blood brain barrier (BBB) as well as the ability to counteract the inherent and adaptive resistance of GBM cancer cells to temozolomide, the current standard of care in GBM. This resistance is largely derived from the expression of the DNA repair enzyme MGMT1. LP-184 activity is agnostic to MGMT expression, meaning it does not depend on the under or over-expression of MGMT in GBM and has shown in-vivo, preclinical activity in both types of GBM models.

No new drugs for GBM have been approved in over two decades. Lantern Pharma is advancing LP-184, a molecule which demonstrates synthetic lethality when combined with agents that cause DNA damage repair deficiency.2 Additionally, LP-184 has shown that it causes double-stranded breaks in the DNA of recurrent GBM (rGBM) cancer cells in multiple in-vivo models and is currently being advanced in early clinical stage studies.

"Receiving FDA Fast Track Designation for Lantern Pharma’s LP-184 in GBM reinforces our belief that this drug-candidate can help in the critical need to find effective treatment options for patients with GBM and further supports the potential of LP-184 to address the challenges in aggressive CNS cancers, where patients have a critical need for novel and life extending therapies" said Panna Sharma, President and CEO of Lantern Pharma.

Current status of LP-184 & STAR-001 in clinical trials & development

LP-184 is currently being studied in a phase 1A clinical trial to evaluate the safety, tolerability and maximum tolerated dose (MTD) of the potential therapy in a wide range of tumors, including GBM. The full study design can be viewed here (clinicaltrials.gov). Once the MTD has been established, Lantern has plans to advance the drug-candidate LP-184 as STAR-001 through its wholly owned subsidiary, Starlight Therapeutics, in GBM and other CNS and brain cancers.

Lantern also anticipates further using RADR to determine potential additional suitability for LP-184 in combination with other approved agents for the control of cancer progression in multiple other patient subgroups. Lantern has provided information on the development of LP-184 in GBM and has also discussed its plan to advance STAR-001 (LP-184 for CNS cancers) in multiple publicly available webinars, including on:

June 26, 2024 — STAR-001 in Multiple Brain and CNS Cancers with Dr. Marc Chamberlain, and
July 31, 2024 — Born from AI, Lighting The Way in CNS Cancer Treatment with Mr. Panna Sharma.
The proposed goals for the development of Phase 1b/2a clinical studies are targeting a rGBM specific trial to begin in late 2024 or early 2025. This trial is being planned to assess LP-184 in a Phase 1b/2a study as mono-therapy and in combination with spironolactone in rGBM to assess safety, pharmacokinetics and preliminary efficacy. Concurrently, Lantern will conduct a retrospective correlative analysis of multiple key markers of DNA damage as exploratory endpoints. EGFR expression or mutation status, MGMT status and expression of DNA damage repair pathway are also planned to be studied as potential response predictors to help inform and guide future late-stage trials and to stratify enrollment.

About the FDA Fast Track process

The FDA’s Fast Track process is designed to facilitate development and expedite the review of therapies intended to treat serious conditions and address unmet medical needs to potentially bring important new medicines to patients sooner. Companies whose programs are granted Fast Track Designation are eligible for more frequent interactions with the FDA during clinical development. For more information on Fast Track designation, please visit the FDA’s website at www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track.

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

On October 15, 2024 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that it has completed the 0.09 mg/kg dose group of the Phase 1 dose escalation portion of the Acclaim-3 clinical trial of Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC) (Press release, Genprex, OCT 15, 2024, View Source [SID1234647201]). In addition, the Safety Review Committee (SRC) has approved escalation to the highest dose group of 0.12 mg/kg. The combination of REQORSA and atezolizumab previously received U.S. Food and Drug Administration’s (FDA) Fast Track Designation for the treatment of the Acclaim-3 patient population and the FDA has also granted Orphan Drug Designation to REQORSA for the treatment of SCLC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We believe the SRC’s recommendation to advance to the highest dose group of the Phase 1 portion of the trial is another clinical validation for our REQORSA development program," said Ryan Confer, President and Chief Executive Officer. "We are proud of the achievements so far in the Phase 1 portion of the trial, which has demonstrated a favorable safety profile for REQORSA in the first trial to use REQORSA for SCLC patients. We look forward to continuing to treat these patients while we work toward bringing new therapies to lung cancer patients with unmet medical need."

There were no dose limiting toxicities (DLTs) in this dose group and the SRC recommended moving up to the highest dose group planned in the trial. As previously announced, the first patient treated in the Phase 1 dose escalation portion of the Acclaim-3 trial had a partial remission, which is defined as at least a thirty percent (30%) decrease in tumor size, from prior to the start of maintenance therapy to the time of the CT scan performed after two cycles of maintenance therapy. A CT scan performed after four cycles of maintenance therapy (three months), confirmed that the patient had a 30% decrease in tumor size in measurable lesions; however, one lesion not previously measurable had grown in size, thus leading to a conclusion of disease progression at that time. As the maintenance therapy consists of REQORSA and Tecentriq, and the patient had already received four cycles of Tecentriq during induction therapy and thus responses to Tecentriq would likely have occurred earlier, the Company believes this suggests that REQORSA may be providing clinical benefit.

The SRC is comprised of three physicians who are principal investigators in the trial. The SRC may recommend that the trial continue at the same dose or at a lower dose, that it escalate to a higher dose, or that the study be terminated altogether due to safety concerns.

In the Phase 1 dose escalation portion of the Acclaim-3 clinical trial, patients are treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. The primary endpoint of the Phase 1 escalation portion is to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D).

The Phase 1 portion of the trial has two dose groups: 0.09 mg/kg, which has been completed, and 0.12 mg/kg which will now be enrolled. After the Phase 1 portion is complete, the Phase 2 expansion portion will enroll 50 patients at 10 to 15 U.S sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. The primary endpoint of the Phase 2 portion is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq in patients with ES-SCLC. Patients will also be followed for survival. A Phase 2 futility analysis will be performed after the 25th patient enrolled and treated reaches 18 weeks of follow up. The Company continues to anticipate completion of enrollment in the Phase 1 dose escalation portion of the trial and to start the Phase 2 expansion portion in the second half of 2024, dependent on the number of patients needed to be enrolled in the 0.12 mg/kg dose group.

Data presented at the October 2023 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) from studies in humanized mouse models of SCLC show that the combination of REQORSA and atezolizumab provides significantly better control of xenograft tumor growth than either agent alone. The data from these studies also demonstrated increased immune cell infiltration in the tumors with the combination of REQORSA and Tecentriq compared to Tecentriq alone.

About Acclaim-3

The Acclaim-3 clinical trial is an open-label, multi-center Phase 1/2 clinical trial evaluating the Company’s lead drug candidate, Reqorsa Gene Therapy, in combination with Genentech, Inc.’s Tecentriq (atezolizumab) as maintenance therapy in patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.

BostonGene and Sarah Cannon Research Institute Collaborate to Accelerate the Development of Targeted Cancer Therapies and Improve Patient Outcomes

On October 15, 2024 BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, and Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, reported a collaboration aimed at integrating innovative molecular testing and informatics platforms into clinical decision-making processes at SCRI phase 1 clinics (Press release, BostonGene, OCT 15, 2024, View Source [SID1234647217]). Additionally, the collaboration seeks to validate novel biomarkers using BostonGene’s AI-powered multiomics platform in real-world cancer populations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This collaboration will establish robust data connectivity between BostonGene and SCRI’s precision medicine platform Genospace. By integrating BostonGene’s advanced testing platform into clinical workflows at community oncology clinics, the effects of molecular profiling on clinical trial enrollment frequency will be examined, including the impact of human leukocyte antigens (HLA) genotyping on pre-screening patients.

"By integrating BostonGene’s advanced molecular profiling into our phase 1 clinical workflows, physicians are poised to significantly enhance our ability to make precise, data-driven treatment decisions. We look forward to the impact we can make in advancing personalized oncology care through our strategic collaboration," said Andrew McKenzie, PhD, Vice President of Personalized Medicine at SCRI and Scientific Director at Genospace.

BostonGene will provide its CLIA-certified, CAP-accredited Tumor PortraitTM tests to clinicians at SCRI’s phase 1 sites. Comprehensive data analyses by Genospace and SCRI will focus on HLA typing, microenvironment profiles, RNA expression levels, gene alterations, trial enrollment, treatment outcomes, therapy duration and other clinically relevant metrics.

"We are thrilled to collaborate with SCRI, integrating our AI-driven multi-omics platform into select community oncology practices. This collaboration will enable us to personalize cancer treatment more effectively and expedite biomarker discovery and validation, ultimately shifting the standard of care and improving patient outcomes," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.